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Introduction
Gastric cancer is the most common cancer in Korea and is the
second leading cause of cancer-related deaths [1]. Approximately 20-
60% of patients who have undergone curative surgery for gastric
cancer develop recurrent diseases [2], and they undergo palliative
chemotherapy.
Palliative chemotherapy has been shown to improve quality of life
and overall survival (OS) compared to the best supportive care [3].
Different first-line treatments for advanced gastric cancer have
response rates (RR) that range from 12-56%, with the median OS not
exceeding 12 months [4,5]. There is no standard first-line treatment for
advanced gastric cancer, yet a 5-fluorouracil (5-FU) and platinum-
based regimen is usually administered. 
Half of the patients receiving chemotherapy are unresponsive, and
the majority of patients who initially responded eventually become
unresponsive to the chemotherapy. These patients are candidates for
Purpose
The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-
fluorouracil (FOLFIRI) as second-line treatment after failure of oxaliplatin, leucovorin and 5-
fluorouracil (FOLFOX) for advanced gastric cancer.
Materials and Methods
Patients who received modified FOLFOX-4 as first-line treatment and then received
sequential modified FOLFIRI for disease progression were included in this study. The
modified FOLFIRI regimen consisted of irinotecan 150 mg/m
2 in a 90-minute intravenous
infusion on day 1, leucovorin (LV) 20 mg/m
2and 5-fluorouracil (5-FU) 400 mg/m
2as a bolus fol-
lowed by 600 mg/m
2 as a 22-hour infusion on days 1 and 2 with the same dose of 5-FU/LV of
modified FOLFOX-4 every 2 weeks.
Results
A total of 32 patients received 126 courses of FOLFIRI chemotherapy. No complete response
was achieved. Three patients (9.4%; 95% confidence interval [CI], 0 to 20.1%) achieved par-
tial response, whereas 11 (34.4%; 95% CI, 17.0 to 51.8%) patients showed stable disease. Di-
sease control rate (complete response, partial responses and stable diseases) was 43.8%
(95% CI, 25.6 to 61.9%) and median follow up duration was 11.3 months (range, 2.23 to 37.9
months). Median time to progression was 2 months (95% CI, 1.49 to 2.51 months), and median
overall survival from the start of FOLFIRI was 5.84 months (95% CI, 4.34 to 7.34 months).
Toxicities were tolerable. 
Conclusion
Modified FOLFIRI as second-line chemotherapy after failure of the modified FOLFOX-4 in
advanced gastric cancer was tolerable but showed a lower response rate. Further study
about retrying 5-FU/LV with irinotecan after failure of the 5-FU/LV combined regimen is
necessary in advanced gastric cancer. 
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second-line chemotherapy. However, the efficacy and benefit of
second-line chemotherapy for advanced gastric cancer has not been
proven, and there is no currently established second-line regimen or
treatment options. Nevertheless, most patients want to receive che-
motherapy if they are able to.                                                                             
New agents such as docetaxel and irinotecan are under study as
second-line chemotherapy for gastric cancer. Irinotecan is a campto-
thecan analog that is converted in vivo to SN-38, which binds to the
topoisomerase I-DNA complex and thereby disrupts DNA replication
and cell division [6]. The mechanism of action of irinotecan is different
from that of fluoropyrimidine, platinum and taxane, and irinotecan has
no cross-resistance with these agents [7,8]. The objective RR of
irinotecan is 13% for gastric cancer patients as a single agent [9]. In
combination with 5-FU and leucovorin (LV), the overall RR was 22-
42%, and the median OS was 7.6-14.0 months for patients with
untreated gastric cancer [10-13]. As second-line chemotherapy, the
overall RR of the modified irinotecan, LV and 5-fluorouracil
(FOLFIRI) regimen was 10-29%, with the median time to progression
(TTP) being 2.3-4 months and the median OS being 5-10.9 months
[14-18].
We treated patients with advanced gastric cancer with the modified
oxaliplatin, LV and 5-fluorouracil (FOLFOX) regimen as first-line
therapy and then with the modified FOLFIRI regimen as second-line
therapy. Our goal in this study was to evaluate the efficacy and toxicity
of the modified FOLFIRI regimen following the modified FOLFOX
regimen for patients with metastatic gastric cancer. 
Materials and Methods
1 Patient eligibility
We retrospectively reviewed all patients with gastric or gastro-
esophageal junction adenocarcinoma who received the modified
FOLFOX-4 regimen as first-line treatment and the modified FOLFIRI
regimen as second-line treatment for disease progression between
January 2003 and August 2008 at Seoul St. Mary’s Hospital. Patients
with histologically confirmed and locally advanced, metastatic, or
recurrent gastric cancer were eligible. Other eligibility criteria included
the age range of 18 to 75 years, an Eastern Clinical Oncology Group
(ECOG) performance status of 2 or less, adequate bone marrow and
organ functions (an absolute neutrophil count1,500/Ǻ L, platelets
75,000/Ǻ L, creatinineģ2.0 mg/dL, serum bilirubinģ2.0 mg/dL and
serum transaminase levelsģ2 times the upper normal limit), no past or
concurrent history of malignancy other than stomach cancer, except for
curatively treated nonmelanoma skin cancer orin situ carcinoma of the
cervix uteri. This study was reviewed and approved by Catholic
Medical Center Institutional Review Board.
2 Treatment schedule
All patients received the modified FOLFOX-4 regimen, and this
consisted of intravenous oxaliplatin 100 mg/m
2 in a 2-hour intravenous
infusion on day 1, LV 20 mg/m
2 and 5-FU 400 mg/m
2 as a bolus
followed by 600 mg/m
2 as a 22-hour infusion on days 1 and 2, every 2
weeks. As a second-line chemotherapy, the modified FOLFIRI
regimen included irinotecan 150 mg/m
2 in a 90-minute intravenous
infusion on day 1, LV 20 mg/m
2 and 5-FU 400 mg/m
2 as a bolus fol-
lowed by 600 mg/m
2 as a 22-hour infusion on days 1 and 2, every 2
weeks. Atropine was not routinely used. All patients received adequate
anti-emetic therapy prior to chemotherapy. Loperamide was prescribed
prophylactically and the patients were instructed to take loperamide in
case of developing diarrhea. Treatment was continued until docu-
mented disease progression, unacceptable toxicity or patient refusal.  
3 Dose modifications
Chemotherapy was delayed if the patient s granulocyte count was
ģ1,500/mm
3 or the platelet count did not return to a minimum of
75,000/mm
3 on the day of infusion. Other toxicities (except alopecia)
were required to be either grade 0 or 1 before another cycle was started.
The 5-FU dosage was reduced by 20% in the next cycle if a related
grade 3 or worse toxicity (mucositis and hand-foot syndrome) oc-
curred. The dose of irinotecan was not reduced by the occurrence of
mucositis or hand-foot syndrome. The dose of irinotecan and 5-FU
were reduced by 20% for grade 4 neutropenia lasting 7 days or more,
neutropenic fever, grade 4 thrombocytopenia, grade 3 thrombo-
cytopenia with bleeding requiring platelet transfusion, and grade 3/4
non-hematologic toxicities other than nausea and vomiting.
4 Assessment of efficacy and toxicity 
Physical examination, chest X-rays, complete blood counts and
biochemical tests were performed before each chemotherapy cycle.
Computed tomography (CT) scans were performed every three cycles
or when disease progression was suspected. The tumor response was
classified according to the Response Evaluation Criteria in Solid
Tumors (RECIST) criteria. If there was no measurable lesion, the
evaluable lesion was assessed. The presence or absence of each lesion
was noted throughout follow-up. The CT scans were reviewed by a
single experienced radiologist (SEJ). The toxicity was evaluated
according to the National Cancer Institute-Common Toxicity Criteria
(NCI-CTC, ver. 3.0) at each cycle.  
5 Statistics
Descriptive statistics were reported as proportions and medians. The
TTP was measured from the first day of FOLFIRI treatment until the
date of disease progression, the date of the last follow-up, or the date ofCancer Res Treat. 2011;43(3):148-153
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the decision to receive palliative care when no further imaging study
had been performed. The OS was measured from the first day of
FOLFIRI chemotherapy until death or the date of the last follow up.
The TTP and OS were estimated by the Kaplan-Meier method. All the
statistical analyses were performed using SPSS ver. 13.0 (SPSS Inc.,
Chicago, IL). 
Results
1 Patient characteristics
A total of 104 patients received modified FOLFOX-4 as first line
chemotherapy for advanced or recurrent gastric cancer between
January 2003 and August 2008 at Seoul St. Mary s Hospital. A total of
37 patients received modified FOLFIRI as second-line chemotherapy
and 32 of these patients were eligible. 
Patient characteristics are summarized in Table 1. The median age
of the patients was 59 years (range, 33 to 72 years). The male to female
ratio was 22 : 10. Thirteen (40.6%) of the patients had an ECOG per-
formance status of 2. Thirty (93.8%) patients had metastatic disease
and only 2 (6.2%) patients had locally advanced disease. Four patients
(12.5%) had gastroesopheal junction adenocarcinoma. Ten (31.25%)
patients had metastases in more than 3 organs, and the most common
metastatic organ was peritoneum. The median hemoglobin level was
10.8 g/dL (range, 7.5 to 14.2 g/dL).
2  Treatment administration and toxicity 
Patients received a total of 126 cycles of FOLFIRI chemotherapy,
with a median of three cycles (range, 1 to 10 cycles) per patient. Dose
reduction was applied in 29 cycles (23.0%) and the chemotherapy
schedule was delayed in 20 cycles (15.9%), primarily due to hemato-
logical toxicity. The toxicities are listed in Table 2. No deaths due to
toxicity occurred and the toxicities were tolerable. The most common
toxicity was anemia in 27 (84.4%) patients. Grade 3 or 4 anemia
occurred in 2 (6.2%) patients. Grade 3 or 4 neutropenia was observed
in 7 (21.9%) patients. The non-hematologic toxicities consisted
primarily of nausea and vomiting. Grade 1 or 2 diarrhea occurred in 2
(6.2%) patients. 
3 Efficacy and survival  
With the intent-to-treat analysis, the overall RR was 9.4% (Table 3).
No patient had a complete response (CR), whereas 3 (9.4%; 95%
confidence interval [CI], 0 to 20.1%) patients achieved partial
responses (PR), and stable diseases (SD) were documented in 11
(34.4%; 95% CI, 17.0 to 51.8%) patients. The disease control rate (CR,
PR and SD) was 43.8% (95% CI, 25.6 to 61.9%). Ten (31.2%; 95%
CI, 14.3 to 48.2%) patients had progressive diseases (PD). The tumor
responses were not evaluated in 8 (25%) patients; 6 patients showed
clinical progression with aggravation of their performance status, while
2 patients were lost to follow-up. Nineteen (59.4%) patients received
third line chemotherapy after failure of FOLFIRI regimen.
The median follow up duration was 11.3 months (range, 2.23 to 37.9
months). The median TTP for the FOLFIRI regimen was 2 months
(95% CI, 1.49 to 2.51 months) (Fig. 1). The median OS was 5.84
Table 1. Patient characteristics
Characteristics No. of patients (%)
Gender
Male 22 (68.75)
Female 10 (31.25)
Median age (range, yr) 59 (33-72)
ECOG performance status
0 8 (25)
1 11 (34.4)
2 13 (40.6)
Extent of disease
Metastatic 27 (84.4)
Recurrent 3 (9.4)
Locally advanced 2 (6.2)
Operation
Curative 3 (9.4)
Palliative 2 (6.2)
Primary site
Unkown 1 (3.1)
Gastroesopheal junction 4 (12.5)
Body 27 (84.4)
Metastatic number
0 1 (3.1)
1 6 (18.8)
2 15 (46.9)
3 10 (31.2)
Metastatic lesion
Liver 6 (18.8)
Peritoneum 21 (65.6)
Bone 7 (21.9)
Measurable lesion
No measurable 10 (31.25)
Measurable 22 (68.75)
Differentiation
Well 0 (0)
Moderate 9 (28.1)
Poor 19 (59.4)
Unknown 4 (12.5)
Median complete blood count (range)
Hemoglobin (g/dL) 10.8 (7.5-14.2)
White blood cell (10
9/L) 5,450 (2,980-16,990)
Plate count (10
9/L) 197 (81-462)
ECOG, Eastern Clinical Oncology Group.Eun Kyoung Jeon, et al_Second Line Chemotherapy in Gastric Cancer
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months (95% CI, 4.34 to 7.34 months) (Fig. 2).
Discussion 
This study assessed the efficacy and toxicity of the FOLFIRI
regimen as second-line treatment after failure of the modified
FOLFOX-4 regimen. The treatment was well-tolerated. The most
predominant grade 3 or 4 toxicity was neutropenia. Febrile neutropenia
was not seen. There was no grade 3 or 4 diarrhea, and only 3 patients
(8.1%) had grade 1 or 2 diarrhea. This low rate of diarrhea, as com-
pared with that of other irinotecan based studies, could be explained by
the low dose of irinotecan and the ethnic differences of uridine
diphosphate glucuronosyltransferase 1 (UGT1A1). Irinotecan is bio-
transformed into its active metabolite SN-38, and SN-38 is inactivated
by UGT1A1 through glucuronidation. Depending on the number of
TA insertions in the TATAA element of the 5' promoter region, the
genotype of the UGT1A1*28 allele is named as the wild-type (6/6), the
heterozygous genotype (6/7) and the homozygous genotype (7/7). The
patients carrying the heterozygous or homozygous genotype ex-
perienced a decreased expression of the UGT1A1 enzyme, resulting in
a lower rate of SN-38 glucuronidation. The association between the
UGT1A1 gene polymorphism and increased toxicity in patients who
received irinotecan-based chemotherapy is well known [6]. Liu et al.
[19] showed the predominance of the UGT1A1 (6/6) genotype in
Asians (76%) compared with 46% in Caucasians [19]. A high rate of
grade 3 or 4 toxic diarrhea (48.9%) was reported at 180 mg/m
2
irinotecan in French patients [11], but this was 10% at 125 mg/m
2 in
American patients [10], and 6% at 180 mg/m
2in Korean patients [15].
There is no standard first-line treatment for advanced gastric cancer,
yet a 5-FU and platinum based regimen is usually administered and a
modified FOLFOX-4 regimen is one of the commonly used regimens.
Several phase II studies have reported the efficacy of the modified
FOLFIRI regimen as a second-line or salvage regimen after failure of a
5-FU combined regimen (Table 4), for which the response rate was 10-
29%. The TTP was 2.3-4 months and the OS was 5-10.9 months. Our
study showed a lower overall RR but had similar disease control rate
(CR, PR and SD) and similar OS with the other studies. This study
included 10 (31.3%) patients without measurable lesions. These pa-
tients only had evaluable lesions and were evaluated for only SD or PD
responses, resulting in a low RR.
Based on the results of the phase III study [20], we used a low dose
of LV. Jäger et al. [20] compared the therapeutic effects and toxicity of
high-dose LV/5-FU versus low-dose LV/5-FU for treating colon
cancer. The high dose LV/5-FU was not superior to the low-dose
LV/5-FU, yet the RR and OS were comparable, but the treatment-
related toxicity was higher in the high dose LV/5-FU group.
A low dose of irinotecan and the same dose of the prior failed regi-
men (5-FU/LV) with same infusion-method could also be reasons for
the low RR and shorter TTP. Also, a synergistic effect of irinotecan
and 5-FU/LV is controversial. In some studies, combining irinotecan
with 5-FU/LV showed synergistic effects after failure of 5-FU/LV [21-
23]. However, the FOLFIRI regimen as the second-line therapy had a
lower response rate than the RR of second-line FOLFOX with the
same dose of 5-FU/LV in advanced colon cancer [24]. In addition, the
efficacy of irinotecan alone was comparable to that of 5-FU/LV and
irinotecan after failure of 5-FU/LV [25]. Therefore, after failure of
FOLFOX, irinotecan single chemotherapy, combination of irinotecan
with other doses of 5-FU/LV can be considered.
NCI-CTCAE grade (%)
G1 G2 G3 G4 All
Non hematologic toxicities
Nausea 5 (15.6) 6 (18.8) 3 (9.4) 0 14 (43.8)
Vomiting 3 (9.4) 6 (18.8) 2 (6.2) 0 11 (34.4)
Diarrhea 1 (3.1) 1 (3.1) 0 0 2 (6.2)
Hepatoxicity 6 (18.8) 0 0 1 (3.1) 7 (21.9)
Hematologic toxicities
Neutropenia 5 (15.6) 7 (21.9) 0 7 (21.9) 19 (59.4)
Anemia 11 (34.4) 13 (40.6) 1 (3.1) 2 (6.2) 27 (84.4)
Thrombocytopenia 3 (9.4) 2 (6.2) 1 (3.1) 0 6 (18.8)
Febrile neutropenia 0 0 0 0 0
Table 2. Toxicity profiles of FOLFIRI (per patient)
FOLFIRI, irinotecan, leucovorin and 5-fluorouracil; NCI-CTCAE ver. 3.0, National Cancer Institute-Common Toxicity Criteria for Adverse Events ver. 3.0.
Table 3. Efficacy of FOLFIRI
Response No. of patients (%) 95% confidence interval
Complete response 0 (0) -
Partial response 3 (9.4) 0-20.1
Stable disease 11 (34.4) 17.0-51.8
Progressive disease 10 (31.2) 14.3-48.2
Not assessable 8 (25) -
FOLFIRI, irinotecan, leucovorin  and 5-fluorouracil.Cancer Res Treat. 2011;43(3):148-153
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Conclusion
The modified FOLFIRI regimen as second-line therapy after failure
of the modified FOLFOX-4 regimen in patients with advanced gastric
cancer was tolerable, but our study showed a lower response rate than
that of other studies on second-line FOLFIRI after failure with various
first-line chemotherapy strategies. Re-administration of failed 5-
FU/LV with the same dose and with the same infusion method in the
modified FOLFIRI regimen could be one of the reasons for this.
Previous 
No. of
chemotherapy
previous  Regimen RR (%) SD (%) TTP (mo) OS (mo)
chemo-regimen
Lorizzo et al. [16] Not restricted, 1 I 180 mg/m
2 D1 21 21 4 5
fluoropyrimidine based,  LV 200 mg/m
2 bolus D1
regimen (71.43%) included, 5-FU 400 mg/m
2 bolus,
no FOLFOX 2,400 mg/m
2 over 46 hr
Assersohn et al. [15] Not restricted, 1 I 180 mg/m
2 D1 29 34 3.7 6.4
fluoropyrimidine based, LV 125 mg/m
2 bolus D1
regimen (97.4%) included, 5-FU 400 mg/m
2 bolus,
no FOLFOX 1,200 mg/m
2 over 48 hr
Seo et al. [14] Not restricted,
fluoropyrimidine based,  1 I 180 mg/m
2 D1 18 29 3.2 9.1
regimen (75%) included, LV 200 mg/m
2 bolus D1, 2
modified FOLFOX  5-FU 400 mg/m
2 bolus,
(29%) included 600 mg/m
2 over 22 hr D1, 2
Kim et al. [18] Fluoropyrimidine based regimen 1 I 150 mg/m
2 D1 18.2 18.2 2.3 5.1
LV 20 mg/m
2 bolus D1, 2
5-FU 3,000 mg/m
2 over 48 hr
Kim et al. [17] Not restricted, 1 I 150 mg/m
2 D1 10 36.7 3.3 10.9
modified FOLFOX  LV 20 mg/m
2 bolus D1, 2
(52.6%) included 5-FU 400 mg/m
2 bolus,
600 mg/m
2 over 22 hr D1, 2
This study Modified FOLFOX 1 I 150 mg/m
2 D1 9.1 34.4 2 5.84
LV 20 mg/m
2 bolus D1, 2
5-FU 400 mg/m
2 bolus, 
600 mg/m
2 over 22 hr D1, 2
Table 4.  Phase II studies on irinotecan, 5-FU, and LV combination chemotherapy for advanced gastric cancer
5-FU, 5-fluorouracil; LV, leucovorin; RR, response rate; SD, stable diseases; TTP, time to progression; OS, overall survival; I, irinotecan; D, day.
0
1.0
12
Probability
of
progression
Time (mo)
0.0
8 6 4 2
0.8
0.6
0.4
0.2
10
Median TTP: 2 mo
(95% confidence interval, 1.49 to 2.51 mo)
Fig. 1. Time to progression (TTP) curve.
0
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Cum
survival
0.0
0.8
0.6
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(95% confidence interval, 4.34 to 7.34 mo)
Time (mo)
10 20 30
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Further study on retrying 5-FU/LV with irinotecan after failure of the
5-FU/LV combined regimen in advanced gastric cancer patients is
necessary. 
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